Monopar Therapeutics Relocates Principal Executive Offices

Ticker: MNPR · Form: 8-K · Filed: 2025-02-24T00:00:00.000Z

Sentiment: neutral

Topics: corporate-actions, filing-update

TL;DR

Monopar Therapeutics moved its HQ to Wilmette, IL.

AI Summary

Monopar Therapeutics Inc. announced on February 19, 2025, a change in its principal executive offices to 1000 Skokie Blvd., Suite 350, Wilmette, IL 60091. This filing is a current report (8-K) under the Securities Exchange Act of 1934.

Why It Matters

A change in principal executive offices can indicate operational shifts or growth for a company. Investors should monitor if this move is associated with expansion or cost-saving measures.

Risk Assessment

Risk Level: low — This filing solely reports a change in the company's principal executive office address and does not involve financial performance, executive changes, or material business events.

Key Players & Entities

FAQ

What is the new address for Monopar Therapeutics' principal executive offices?

The new address for Monopar Therapeutics' principal executive offices is 1000 Skokie Blvd., Suite 350, Wilmette, IL 60091.

What is the date of the earliest event reported in this 8-K filing?

The date of the earliest event reported is February 19, 2025.

What type of SEC filing is this?

This is a Form 8-K, a Current Report filed pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934.

Under which state is Monopar Therapeutics incorporated?

Monopar Therapeutics Inc. is incorporated in Delaware.

What is the telephone number for Monopar Therapeutics?

The telephone number for Monopar Therapeutics, including area code, is (847) 388-0349.

From the Filing

0001437749-25-004910.txt : 20250224 0001437749-25-004910.hdr.sgml : 20250224 20250224171528 ACCESSION NUMBER: 0001437749-25-004910 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20250219 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20250224 DATE AS OF CHANGE: 20250224 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Monopar Therapeutics CENTRAL INDEX KEY: 0001645469 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 320463781 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39070 FILM NUMBER: 25658184 BUSINESS ADDRESS: STREET 1: 1000 SKOKIE BLVD SUITE 350 CITY: WILMETTE STATE: IL ZIP: 60091 BUSINESS PHONE: 8473880349 MAIL ADDRESS: STREET 1: 1000 SKOKIE BLVD SUITE 350 CITY: WILMETTE STATE: IL ZIP: 60091 8-K 1 mnpr20250221_8k.htm FORM 8-K mnpr20250221_8k.htm false 0001645469 0001645469 2025-02-19 2025-02-19     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549   FORM 8-K   CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934   Date of Report (Date of earliest event reported): February 19, 2025   MONOPAR THERAPEUTICS INC. (Exact name of registrant as specified in its charter)   Delaware   001-39070   32-0463781 (State or other jurisdiction of incorporation)   (Commission File Number)   (I.R.S. Employer Identification No.)   1000 Skokie Blvd. , Suite 350 , Wilmette , IL   60091 (Address of principal executive offices)   (Zip Code)   ( 847 ) 388-0349 Registrant’s telephone number, including area code   N/A (Former name or former address, if changed since last report)   Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common Stock, $0.001 par value   MNPR   The Nasdaq Stock Market LLC (Nasdaq Capital Market)   Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)   ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)   ☐  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))   ☐  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))   Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).   Emerging growth company  ☐   If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐           Item 5.02     Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.   Michael J. Brown has resigned from his position as a member of the Monopar Therapeutics Inc. (the” Company”) Board of Directors (the “Board”) effective February 19, 2025.   On February 21, 2025, the Company’s Board appointed Lavina Talukdar to the Board. The Corporate Governance

View on Read The Filing